Purpose: to compare the vault changes, anterior segment parameters, and intraocular pressure
(IOP) after pharmacological mydriasis by tropicamide 1% and cyclopentolate 1% in moderateto-high myopic eyes with Implantable Phakic Contact Lens (IPCL). Methods: a prospective
observational study 48 myopic eyes were implanted with IPCL V2.0 (Care group Sight Solutions,
India). Pharmacological mydriasis was done by tropicamide 1% and cyclopentolate 1%. The patients
were divided into 2 groups, group 1 was dilated by tropicamide1 % and group 2 was dilated by
cyclopentolate 1%. The Pentacam was used to evaluate the lens vault, anterior chamber depth
(ACD), anterior chamber volume (ACV), pupil size, and endothelium-IPCL (end-IPCL). Also, IOP
was evaluated and compared between both groups. Results: the Pentacam study of both groups
revealed significant changes regarding the vault, ACD, ACV, and pupil size with no significant
difference in end-IPCL (p-value= 0.884 and 0.880) in groups 1 and 2 respectively. And no significant
difference when comparing both groups with each other. Regarding IOP, there was a significant
difference in both groups with no significant difference when comparing both groups with each
other (p-value=.295). Conclusion: pharmacological mydriasis in myopic eyes implanted with IPCL
results in changes in the vault, ACD, and ACV with no significant difference between tropicamide 1%
and cyclopentolate 1%. Both medications caused IOP elevation to a similar value so there was
a need to recheck IOP post dilatation preferably at 45 minutes. So mydriasis with either tropicamide
1 % or cyclopentolate 1 % was relatively safe in eyes with IPCL implantation.